<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Acta biomedica scientifica</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Acta biomedica scientifica</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Acta biomedica scientifica</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2541-9420</issn>
   <issn publication-format="online">2587-9596</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">14777</article-id>
   <article-id pub-id-type="doi">10.12737/23735</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Клиническая медицина</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Clinical Medicine</subject>
    </subj-group>
    <subj-group>
     <subject>Клиническая медицина</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">ANTISEPTICS AT INTRAVITREAL INJECTIONS</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>АНТИСЕПТИКИ ПРИ ИНТРАВИТРЕАЛЬНЫХ ИНЪЕКЦИЯХ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Толчинская</surname>
       <given-names>Анна Ивановна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Tolchinskaya</surname>
       <given-names>Anna Ивановна</given-names>
      </name>
     </name-alternatives>
     <email>atolchinskaya@mail.ru</email>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Иошин</surname>
       <given-names>Игорь Эдуардович</given-names>
      </name>
      <name xml:lang="en">
       <surname>Ioshin</surname>
       <given-names>Igor Эдуардович</given-names>
      </name>
     </name-alternatives>
     <email>igor.ioshin@gmail.com</email>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Оздербаева</surname>
       <given-names>Айна Альвиевна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Ozderbaeva</surname>
       <given-names>Ayna Альвиевна</given-names>
      </name>
     </name-alternatives>
     <email>aina3000@mail.ru</email>
    </contrib>
   </contrib-group>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2016-12-23T00:00:00+03:00">
    <day>23</day>
    <month>12</month>
    <year>2016</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2016-12-23T00:00:00+03:00">
    <day>23</day>
    <month>12</month>
    <year>2016</year>
   </pub-date>
   <volume>1</volume>
   <issue>6</issue>
   <fpage>55</fpage>
   <lpage>59</lpage>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/14777/view">https://zh-szf.ru/en/nauka/article/14777/view</self-uri>
   <abstract xml:lang="ru">
    <p>Дан анализ эффективности применения антисептика мирамистина (Окомистин®) в профилактике инфекционных осложнений при многократных интравитреальных инъекциях ингибитора VEGF ранибизумаба у больных с возрастной макулярной дегенерацией. Показано, что асептический и антисептический уровень – определяющие в профилактике инфекционных осложнений при выполнении интравитреальных инъекций. В качестве дополнительной профилактики успешно апробирован антисептик Окомистин®, обеспечивающий высокий уровень противомикробной защиты в отсутствие риска развития резистентности.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Authors analyze efficiency of application antiseptics of a miramistin in prevention of infectious complications in case of repeated intravitreal injections of VEGF inhibitor Ranibizumab in 156 patients with the age related macular de-generation. 0,01% solution of antiseptic Miramistin (Okomistin®) was instillated 4 times per day two days before operation to all patients for the purpose of infection prevention. Just before the operation (60 and 30 minutes before) and right after it instillations of antiseptic continued within a week after intravitreal injection. During the operation in the conditions of the operating room with keeping of all rules of aseptic, three minutes prior to operation the surgery field and the conjunctival cavity of the patient were twice processed by 5% povidone-iodine solution (Betadine). The results analysis showed no expressed signs of irritation of the eyes connected to miramistin treatment preceding the operation. In the postoperative period all patients endured antiseptics well. Within a week of applications there were no complaints about pain, burning, foreign body sensation or hazy vision after the medicine instillation, and biomicroscopic research revealed no signs of inflammatory injection of conjunctiva or sclera, no cornea epitheliopathy, there was no cellular response in moisture of the anterior chamber and vitreous body. Thus, the authors state that antiseptics Okomistin® as an additional measure of prevention of infectious complications in case of intravitreal injection provide high level antimicrobic protection with no risk of development of microbial resistance. </p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>интравитреальные инъекции</kwd>
    <kwd>эндофтальмит</kwd>
    <kwd>профилактика</kwd>
    <kwd>антисептики</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>intravitreal injections</kwd>
    <kwd>endophthalmitis</kwd>
    <kwd>prevention</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">БелоусовЮ.Б. Антибиотикотерапия сегодня //Вопросы врачебнойпрактики. - 2010. - No9. - С.54-57.</mixed-citation>
     <mixed-citation xml:lang="en">BelousovYB (2010). Antibiotic therapy today [Antibiotikoterapiya segodnya]. Voprosy vrachebnoy praktiki, (9), 54-57</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">БойкоЭ.В., СосновскийС.В. Ангиогенная тера-пия вофтальмологии. - СПб.: ВМедА им. С.М.Кирова, 2013. - 286c</mixed-citation>
     <mixed-citation xml:lang="en">BoykoEV, SosnovskiySV (2013). Angiogenic therapy inophthalmology [Angiogennaya terapiya v oftal’mologii], 286.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ВохмяковА.В., ОколовИ.Н., ГурченокП.А. Вы-бор оптимального антибиотика для профилактики инфекционных осложнений в офтальмохирургии (обзор литературы) //Клиническаяофтальмоло-гия.- 2007. - No1, Т.8. - С.37-40</mixed-citation>
     <mixed-citation xml:lang="en">VokhmyakovAV, OkolovIN, GurchenokPA (2007). Choosing the best antibiotic for prevention of infectious complications in ophthalmic surgery (review) [Vybor optimal’nogo antibiotika dlya profilaktiki infektsionnykh oslozhneniy v oftal’mokhirurgii (obzor literatury)]. Klinicheskaya oftal’mologiya, 1(8), 37-40.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ГейсекЛ., СтепановА.К., БэнешоваЖ., НемецП., РеймонтЛ., ЭрнестЯ., РозсивалП. Инфекционные ос-ложнения при интравитреальном введении ингиби-торов VEGF при лечении влажной формы возрастной макулярной дегенерации //Российский офтальмоло-гический журнал. - 2013. - No3. - С.20-24.</mixed-citation>
     <mixed-citation xml:lang="en">GeysekL, StepanovAK, BeneshovaZ, NemetsP,ReymontL, ErnestY, RozsivalP (2013). Infectious complications of intravitreal VEGF inhibitors for the treatment of wet age-related macular degeneration [Infektsionnye oslozhneniya pri intravitreal’nom vvedenii ingibitorov VEGF pri lechenii vlazhnoy formy vozrastnoy makulyarnoy degeneratsii]. Rossiyskiy oftal’mologicheskiy zhurnal, (3), 20-24.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ЕгоровЕ.А., ГундороваР. А., КривошеинЮ.С., АлексееваИ.Б., СмоктийЮ.М., АсророваГ.К., Гал-чинА.А. Применение Мирамистина в офтальмологии. Пособие для врачей. - М., 2003. - 8с.</mixed-citation>
     <mixed-citation xml:lang="en">EgorovEA, GundorovaRA, KrivosheinYS, AlekseevaIB, SmoktiyYM, AsrorovaGK, GalchinAA (2003). Application of Miramistin in ophthalmology. The guidelines for physicians [Primenenie Miramistina v oftal’mologii. Posobie dlya vrachey], 8.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ИошинИ.Э., ТолчинскаяА.И., ТагиеваР.Р., Ду-бровскаяС.А. Эффективность применения ингибито-ра ангиогенеза Ранибизумаба (Луцентиса) в лечении неоваскулярной возрастной макулярной дегенерации //Российский офтальмологическийжурнал. - 2011.- No2. - С.21-27</mixed-citation>
     <mixed-citation xml:lang="en">IoshinIE, TolchinskayaAI, TagievaRR, DubrovskayaSA(2011) The effectiveness of angiogenesis inhibitor Ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration [Effektivnost’ primeneniya ingibitora angiogeneza Ranibizumaba (Lutsentisa) v lechenii neovaskulyarnoy vozrastnoy makulyarnoy degeneratsii]. Rossiyskiy oftal’mologicheskiy zhurnal, (2), 21-27.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ИошинИ.Э., ТолчинскаяА.И. Профилактика инфекционных воспалительных осложнений при фа-коэмульсификации катаракты //Eye World. - 2011.- Т.4, No3. - С.52-53.</mixed-citation>
     <mixed-citation xml:lang="en">IoshinIE, TolchinskayaAI (2011). Prevention of infectious inflammatory complications in cataract phacoemulsification [Profilaktika infektsionnykh vospalitel’nykh oslozhneniy pri fakoemul’sifikatsii katarakty]. Eye World, 4(3), 52-53.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">МайчукЮ.Ф., СеливерстоваК.Е., ЯкушинаЛ.Н. Антисептик Окомистин в лечении бактериальных за-болеваний глаз //Катарактальная и рефракционная хирургия. - 2011. - Т.11, No2. - С.59-64.</mixed-citation>
     <mixed-citation xml:lang="en">MaichukYF, SeliverstovaKE, YakushinaLN (2011) Antiseptic Okomistin in treatment of bacterial diseases of the eye [Antiseptik Okomistin v lechenii bakterial’nykh zabolevaniy glaz]. Kataraktal’naya i refraktsionnaya khirurgiya,11(2), 59-64.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">ОколовИ.Н., ГурченокП.А. Резистентность к антибиотикам нормальной микрофлоры конъюн-ктивы у пациентов перед офтальмохирургическими операциями //Офтальмологические ведомости. - 2008. - No1, Т.4. - С 59-62</mixed-citation>
     <mixed-citation xml:lang="en">OkolovIN, GurchenokPA (2008). Antibiotic re-sistance of normal flora of the conjunctiva of patients prior to ophthalmic operations [Rezistentnost’ k antibiotikam normal’noy mikroflory kon’yunktivy u patsientov pered oftal’mokhirurgicheskimi operatsiyami]. Oftal’mologicheskie vedomosti, 1(4), 59-62.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Руководство ESCRS по профилактике и ле-чению эндофтальмита после удаления катаракты: данные, дилеммы и выводы. -2013. - Режим доступа: www.escrs.org.</mixed-citation>
     <mixed-citation xml:lang="en">ESCRS guidelines on prevention and treatment of endophthalmitis after cataract surgery: data, dilemmas and conclusions (2013) [Rukovodstvo ESCRS po profilaktike i lecheniyu endoftal’mita posle udaleniya katarakty: dannye, dilemmy i vyvody]. Available at: www.escrs.org.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">СарыгинаО.И., БычковП.А. Профилактика инфекционных осложнений при интравитреальных введениях ранибизумаба //Российский офтальмоло-гический журнал. - 2014. - No2. - С.62-66.</mixed-citation>
     <mixed-citation xml:lang="en">SaryginaOI, BychkovPA (2014) Prevention of infectious complications at intravitreal ranibizumab injections [Profilaktika infektsionnykh oslozhneniy pri intravitreal’nykh vvedeniyakh ranibizumaba]. Rossiyskiy oftal’mologicheskiy zhurnal, (2), 62-66.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">СтебневС.Д. Опыт использования лекарствен-ного препарата Окомистин в пред- и послеопераци-онном периоде у пациентов с катарактой //Офталь-мология. - 2012. - Т.9, No4. - С.69-72.</mixed-citation>
     <mixed-citation xml:lang="en">StebnevSD (2012). Experience in the use of Okomistin medicine in pre- and postoperative period in patients with cataracts [Opyt ispol’zovaniya lekarstvennogo preparata Okomistin v pred- i posleoperatsionnom periode u patsientov s kataraktoy]. Oftal’mologiya, 9(4), 69-72.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">BarryP, SealDV, GettinbyG, LeesF, PetersonM, RevieCW (2006). ESCRS study of prophylaxis of postoperative endophthalmitis after cataract Surgery: Preliminary report of principal results from a European multicenter study. J. Cataract Refract Surg., 32(3), 407-410.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">MarangonFB, MillerD, MuallemMS (2004).Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am. J. Ophthalmol., 137(3), 453-458.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru"></mixed-citation>
     <mixed-citation xml:lang="en">RegilloCD, BrownDM, AbrahamP, YueH,IanchulevT, SchneiderS. et al. (2008) Randomized, double-masket, sham-controlled trial of ranibizumab for neovascular age-relared macular degeneration: PIER Study year 1. Am. J. Ophthalmol., 145(2), 239-248.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
